PL2297152T3 - Bezwodna postać krystaliczna maleinianu orwepitantu - Google Patents

Bezwodna postać krystaliczna maleinianu orwepitantu

Info

Publication number
PL2297152T3
PL2297152T3 PL09731234T PL09731234T PL2297152T3 PL 2297152 T3 PL2297152 T3 PL 2297152T3 PL 09731234 T PL09731234 T PL 09731234T PL 09731234 T PL09731234 T PL 09731234T PL 2297152 T3 PL2297152 T3 PL 2297152T3
Authority
PL
Poland
Prior art keywords
crystal form
anhydrous crystal
orvepitant maleate
orvepitant
maleate
Prior art date
Application number
PL09731234T
Other languages
English (en)
Inventor
Stefania Beato
Franco Sartor
Ian Philip Steeples
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of PL2297152T3 publication Critical patent/PL2297152T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
PL09731234T 2008-04-11 2009-04-09 Bezwodna postać krystaliczna maleinianu orwepitantu PL2297152T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate
PCT/EP2009/054295 WO2009124996A1 (en) 2008-04-11 2009-04-09 Anhydrous crystal form of orvepitant maleate
EP09731234.2A EP2297152B1 (en) 2008-04-11 2009-04-09 Anhydrous crystal form of orvepitant maleate

Publications (1)

Publication Number Publication Date
PL2297152T3 true PL2297152T3 (pl) 2015-04-30

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09731234T PL2297152T3 (pl) 2008-04-11 2009-04-09 Bezwodna postać krystaliczna maleinianu orwepitantu

Country Status (27)

Country Link
US (1) US8309553B2 (pl)
EP (1) EP2297152B1 (pl)
JP (2) JP5875863B2 (pl)
KR (1) KR20110002090A (pl)
CN (1) CN102066376B (pl)
AR (1) AR071311A1 (pl)
AU (1) AU2009235440B2 (pl)
BR (1) BRPI0911678B8 (pl)
CA (1) CA2721119C (pl)
CL (1) CL2009000876A1 (pl)
CY (1) CY1115961T1 (pl)
DK (1) DK2297152T3 (pl)
EA (1) EA017082B1 (pl)
ES (1) ES2529295T3 (pl)
GB (1) GB0806652D0 (pl)
HR (1) HRP20141196T1 (pl)
IL (1) IL208597A0 (pl)
MX (1) MX2010011152A (pl)
PE (1) PE20091839A1 (pl)
PL (1) PL2297152T3 (pl)
PT (1) PT2297152E (pl)
RS (1) RS53732B1 (pl)
SI (1) SI2297152T1 (pl)
TW (1) TW201002714A (pl)
UY (1) UY31758A (pl)
WO (1) WO2009124996A1 (pl)
ZA (1) ZA201007120B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8139718B2 (en) * 2007-10-30 2012-03-20 Elekta Ab (Publ) Radiotherapy apparatus
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
EP2906219B1 (en) 2012-10-11 2019-08-07 NeRRe Therapeutics Limited Orvepitant for the treatment of chronic pruritus
BR112018013903B1 (pt) * 2016-01-08 2023-11-07 Nerre Therapeutics Limited Usos de orvepitante ou de uma composição que compreende o mesmo para tratar tosse crônica
EP3609495A4 (en) 2017-04-10 2020-12-02 Chase Therapeutics Corporation NK1 ANTAGONIST COMBINATION AND METHOD OF TREATMENT OF SYNUCLEINOPATHIA
AU2018290889A1 (en) 2017-06-30 2020-02-13 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CA3173697A1 (en) * 2020-04-03 2021-10-07 Mike TROWER An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
AU2021285503A1 (en) 2020-06-02 2022-12-08 Nerre Therapeutics Limited Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MX2008014840A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US20100308579A1 (en) * 2007-11-02 2010-12-09 Entegris, Inc. Integral face seal
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
AR071311A1 (es) 2010-06-09
ES2529295T3 (es) 2015-02-18
CA2721119C (en) 2016-04-05
CA2721119A1 (en) 2009-10-15
AU2009235440A1 (en) 2009-10-15
PE20091839A1 (es) 2010-01-07
CN102066376A (zh) 2011-05-18
MX2010011152A (es) 2010-12-21
HRP20141196T1 (hr) 2015-02-13
UY31758A (es) 2009-11-10
JP5875863B2 (ja) 2016-03-02
WO2009124996A1 (en) 2009-10-15
CY1115961T1 (el) 2017-01-25
EP2297152A1 (en) 2011-03-23
CN102066376B (zh) 2014-01-01
CL2009000876A1 (es) 2010-05-14
TW201002714A (en) 2010-01-16
SI2297152T1 (sl) 2015-02-27
EA017082B1 (ru) 2012-09-28
US8309553B2 (en) 2012-11-13
US20110166150A1 (en) 2011-07-07
EA201071183A1 (ru) 2011-06-30
GB0806652D0 (en) 2008-05-14
ZA201007120B (en) 2011-11-30
IL208597A0 (en) 2010-12-30
AU2009235440B2 (en) 2012-06-14
DK2297152T3 (da) 2015-01-26
BRPI0911678B8 (pt) 2021-05-25
JP2011516532A (ja) 2011-05-26
RS53732B1 (en) 2015-06-30
JP2014205688A (ja) 2014-10-30
KR20110002090A (ko) 2011-01-06
BRPI0911678A2 (pt) 2015-10-13
BRPI0911678B1 (pt) 2021-03-02
PT2297152E (pt) 2015-02-16
EP2297152B1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
HUS1800015I1 (hu) Kristályok
IL208597A0 (en) Anhydrous crystal form of orvepitant maleate
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA201006754B (en) Crystal of benzimidazole compound
HK1160925A1 (zh) 組織蛋白酶 的用途
GB0813840D0 (en) Improved liquid crystal compounds
GB0908006D0 (en) New crystal form
GB0822248D0 (en) Crystal meths
EP2285776A4 (en) STABILIZATION OF TRIPHENYLBORE-PYRIDINE
EP2132171A4 (en) NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES
GB0806103D0 (en) Improvements to viewing devices
IL189405A0 (en) Stabilization of siva2
ZA201100141B (en) Stable crystal modifications of dopc
IL211688A0 (en) Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate
GB2457157B (en) Crystal unit
TWM347258U (en) Structure of chisel
GB0811620D0 (en) Crystal structure